Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2026-03-12FDA Approved: TRULICITY — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for Trulicity (dulaglutide) submitted by Eli Lilly and Company.
-
FDA approval · 2026-03-04FDA Approved: GLIPIZIDE — Original Application (Graviti Pharmaceuticals Private Limited)
FDA approved the Original Application for GLIPIZIDE tablets from Graviti Pharmaceuticals Private Limited (ANDA 219159), enabling the marketi…
-
EMA approval · 2026-02-26EMA Authorised: Mounjaro (tirzepatide) — Eli Lilly Nederland B.V.
The EMA authorised Mounjaro (tirzepatide) for adults with type 2 diabetes and for obesity/overweight, granting EU marketing authorisation to…
-
FDA approval · 2026-02-24FDA Approved: LIRAGLUTIDE — Original Application (Biocon Pharma Inc.)
The FDA approved Biocon Pharma Inc.'s liraglutide original application (ANDA 217063), providing a generic version of liraglutide.
-
FDA approval · 2026-02-24FDA Approved: LIRAGLUTIDE — Original Application (Orbicular Pharmaceutical Technologies Private Limited)
FDA approved the original application for a generic liraglutide product from Orbicular Pharmaceutical Technologies Private Limited.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-02-12EMA Authorised: Kyinsu (insulin icodec;semaglutide) — Novo Nordisk A/S
The EMA authorised Kyinsu, a fixed-dose combination of insulin icodec and semaglutide, for type 2 diabetes mellitus, with Novo Nordisk A/S a…
-
EMA approval · 2026-02-12EMA Authorised: Jentadueto (linagliptin;metformin) — Boehringer Ingelheim International GmbH
The EMA authorised marketing of Jentadueto, a fixed-dose combination of linagliptin and metformin, for type 2 diabetes mellitus.
-
EMA approval · 2026-02-12EMA Authorised: Trajenta (linagliptin) — Boehringer Ingelheim International GmbH
The EMA authorised Trajenta (linagliptin) by Boehringer Ingelheim International GmbH for the treatment of Type 2 diabetes mellitus. This mar…
-
EMA approval · 2026-02-11EMA Authorised: Steglatro (ertugliflozin l-pyroglutamic acid) — Merck Sharp & Dohme B.V.
The EMA authorised Steglatro (ertugliflozin l-pyroglutamic acid) from Merck Sharp & Dohme B.V. for type 2 diabetes mellitus.
-
FDA approval · 2026-01-30FDA Approved: OZEMPIC — Supplemental Application (Novo Nordisk)
The FDA approved a supplemental application for Ozempic to include the oral semaglutide formulation, expanding its regulatory scope to the o…
-
EMA approval · 2026-01-30EMA Authorised: Trulicity (dulaglutide) — Eli Lilly Nederland B.V.
The EMA authorised Trulicity (dulaglutide) from Eli Lilly Nederland B.V. for use in Type 2 diabetes mellitus in the European Union. The deci…
-
EMA approval · 2026-01-26EMA Authorised: Dapagliflozin Viatris (dapagliflozin) — Viatris Limited
EMA authorised Dapagliflozin Viatris for type 2 diabetes mellitus, heart failure, and chronic kidney disease, with Viatris Limited as the ma…
-
EMA approval · 2026-01-16EMA Authorised: Kerendia (Finerenone) — Bayer AG
The European Medicines Agency authorised Kerendia (finerenone) from Bayer AG for the treatment of chronic kidney disease in adults with type…
-
EMA approval · 2026-01-16EMA Authorised: Victoza (liraglutide) — Novo Nordisk A/S
The European Medicines Agency authorised Victoza (liraglutide) for the treatment of Type 2 diabetes mellitus.
-
FDA approval · 2026-01-14FDA Approved: SITAGLIPTIN PHOSPHATE — Original Application (Sandoz Inc)
FDA approved an original application for sitagliptin phosphate from Sandoz Inc, establishing the generic availability of sitagliptin phospha…
-
FDA approval · 2026-01-14FDA Approved: LIRAGLUTIDE — Original Application (Orbicular Pharmaceutical Technologies Private Limited)
FDA approves the original application for a generic liraglutide product from Orbicular Pharmaceutical Technologies Private Limited.
-
FDA approval · 2026-01-07FDA Approved: MOUNJARO — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for MOUNJARO (tirzepatide) from Eli Lilly and Company.
-
EMA approval · 2026-01-05EMA Authorised: Jalra (vildagliptin) — Novartis Europharm Limited
The European Medicines Agency authorised Jalra (vildagliptin) for the treatment of type 2 diabetes mellitus. Novartis Europharm Limited is t…
-
EMA approval · 2026-01-05EMA Authorised: Xiliarx (vildagliptin) — Novartis Europharm Limited
The EMA authorised Xiliarx, a vildagliptin-containing medicine, for Type 2 diabetes mellitus, with Novartis Europharm Limited as the marketi…
-
EMA approval · 2025-12-18EMA Authorised: Invokana (canagliflozin) — Janssen-Cilag International NV
The EMA has authorised Invokana (canagliflozin) for use in Type 2 diabetes mellitus; the marketing authorization holder is Janssen-Cilag Int…
-
EMA approval · 2025-12-08EMA Authorised: Eucreas (vildagliptin;metformin hydrochloride) — Novartis Europharm Limited
The European Medicines Agency authorised Eucreas, a fixed-dose combination of vildagliptin and metformin, for Type 2 diabetes mellitus. The …
-
EMA approval · 2025-12-05EMA Authorised: Icandra (previously Vildagliptin / metformin hydrochloride Novartis) (vildagliptin;metformin hydrochloride) — Novartis Europharm Limited
The EMA authorised Icandra, a fixed-dose combination of vildagliptin and metformin hydrochloride, for Type 2 diabetes mellitus. The marketin…
-
EMA approval · 2025-12-05EMA Authorised: Zomarist (vildagliptin;metformin hydrochloride) — Novartis Europharm Limited
The EMA authorised Zomarist, a fixed-dose combination of vildagliptin and metformin hydrochloride, for treatment of type 2 diabetes mellitus…
-
FDA approval · 2025-12-02FDA Approved: SITAGLIPTIN AND METFORMIN HYDROCHLORIDE — Original Application (Sandoz Inc)
FDA approved a generic sitagliptin and metformin hydrochloride tablet from Sandoz in an Original Application (ANDA 202388).
-
EMA approval · 2025-12-01EMA Authorised: Efficib (sitagliptin;metformin hydrochloride) — Merck Sharp and Dohme B.V
EMA authorised Efficib, a fixed-dose combination tablet of sitagliptin and metformin for type 2 diabetes mellitus; Merck Sharp & Dohme B.V. …